GGrantIndex
← Leaderboards

Sunil R Hingorani

Fred Hutchinson Cancer Research Center

$16,951,051
Attributed
$17,588,107
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.5M · FY200725
$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,588,107 · 9

By mechanism

R01$11,409,164 · 3
U01$3,302,739 · 1
R21$1,274,112 · 3
N01$1,073,907 · 1
K08$528,185 · 1

Top collaborators

Most similar at Fred Hutchinson Cancer Research Center

Same institution · by research overlap

Others in their field

Top investigators on “Pancreatic Ductal Adenocarcinoma

Research focus

Pancreatic Ductal AdenocarcinomaMalignant Neoplasm Of PancreasCessation Of LifeCancer EtiologyCellsMolecularInvestigationEpithelial CellsSignal TransductionPathogenesisProgramsAnimal ModelHuman DiseaseIncidenceGenetically Engineered MouseMalignant NeoplasmsBehaviorEngineeringNeoplasm MetastasisResponseTumorCountryOrganResistance

Grant awards (45)

OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER$463,532
R01 · FY2025 · CA · contact PI
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER$448,893
R01 · FY2024 · CA · contact PI
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER$497,998
R01 · FY2023 · CA · contact PI
Investigating the metastatic drive in pancreas cancer$327,136
R01 · FY2022 · CA · contact PI
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER$322,912
R01 · FY2022 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$265,568
R01 · FY2022 · CA · contact PI
Investigating the metastatic drive in pancreas cancer$90,215
R01 · FY2022 · CA · contact PI
Disrupting the immune and drug-privileged microenvironment in pancreas cancer$345,859
U01 · FY2021 · CA · contact PI
Investigating the metastatic drive in pancreas cancer$258,637
R01 · FY2021 · CA · contact PI
Disrupting the immune and drug-privileged microenvironment in pancreas cancer$257,096
U01 · FY2021 · CA · contact PI
Stopping PDA progression using inhibitors of CSC dissemination and immunotherapy$250,000
U01 · FY2021 · CA · contact PI
Investigating the metastatic drive in pancreas cancer$216,163
R01 · FY2021 · CA · contact PI
Disrupting the immune and drug-privileged microenvironment in pancreas cancer$602,955
U01 · FY2020 · CA · contact PI
Investigating the metastatic drive in pancreas cancer$545,387
R01 · FY2020 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$513,401
R01 · FY2020 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$1
R01 · FY2020 · CA · contact PI
Investigating the metastatic drive in pancreas cancer$529,025
R01 · FY2019 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$497,999
R01 · FY2019 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$513,402
R01 · FY2018 · CA · contact PI
Investigating the metastatic drive in pancreas cancer$474,800
R01 · FY2018 · CA · contact PI
Disrupting the immune and drug-privileged microenvironment in pancreas cancer$1,846,829
U01 · FY2017 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$620,121
R01 · FY2017 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$525,536
R01 · FY2016 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$506,216
R01 · FY2015 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$494,110
R01 · FY2014 · CA · contact PI
Minimally invasive ablative therapies for pancreatic cystic neoplasms$175,314
R21 · FY2014 · CA
Overcoming stromal barriers to therapeutics in pancreas cancer$479,510
R01 · FY2013 · CA · contact PI
Genetic progression of pancreatic mucinous cystic neoplasms to invasive carcinoma$331,820
R01 · FY2013 · CA · contact PI
Minimally invasive ablative therapies for pancreatic cystic neoplasms$232,641
R21 · FY2013 · CA
Peripheral blood biopsy for molecular diagnosis of pancreatic cancer$185,906
R21 · FY2013 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$509,832
R01 · FY2012 · CA · contact PI
Genetic progression of pancreatic mucinous cystic neoplasms to invasive carcinoma$353,000
R01 · FY2012 · CA · contact PI
Peripheral blood biopsy for molecular diagnosis of pancreatic cancer$266,061
R21 · FY2012 · CA · contact PI
Overcoming stromal barriers to therapeutics in pancreas cancer$524,117
R01 · FY2011 · CA · contact PI
Genetic progression of pancreatic mucinous cystic neoplasms to invasive carcinoma$353,000
R01 · FY2011 · CA · contact PI
Dissecting the roles of stellate cells in pancreas cancer progression$222,790
R21 · FY2011 · CA
BIOMEDICAL (BASIC)$583,493
N01 · FY2010 · WH · contact PI
Genetic progression of pancreatic mucinous cystic neoplasms to invasive carcinoma$369,582
R01 · FY2010 · CA · contact PI
Dissecting the roles of stellate cells in pancreas cancer progression$191,400
R21 · FY2010 · CA
Molecular and Cellular Origins of Pancreatic Cancer$148,092
K08 · FY2010 · CA · contact PI
BIOMEDICAL (BASIC)$490,414
N01 · FY2009 · WH · contact PI
Genetic progression of pancreatic mucinous cystic neoplasms to invasive carcinoma$377,251
R01 · FY2009 · CA · contact PI
Molecular and Cellular Origins of Pancreatic Cancer$109,553
K08 · FY2009 · CA · contact PI
Molecular and Cellular Origins of Pancreatic Cancer$135,270
K08 · FY2008 · CA · contact PI
Molecular and Cellular Origins of Pancreatic Cancer$135,270
K08 · FY2007 · CA · contact PI